Loganathan Archana, Manohar Prasanth, Eniyan Kandasamy, VinodKumar C S, Leptihn Sebastian, Nachimuthu Ramesh
School of Bioscience and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu India.
Zhejiang University-University of Edinburgh (ZJU-UoE) Institute, Zhejiang University, School of Medicine, Haining, 314400 Zhejiang People's Republic of China.
Beni Suef Univ J Basic Appl Sci. 2021;10(1):49. doi: 10.1186/s43088-021-00141-8. Epub 2021 Aug 28.
Antibiotic resistance among pathogenic bacteria has created a global emergency, prompting the hunt for an alternative cure. Bacteriophages were discovered over a century ago and have proven to be a successful replacement during antibiotic treatment failure. This review discusses on the scientific investigation of phage therapy for Gram-positive pathogens and general outlook of phage therapy clinical trials and commercialization.
This review aimed to highlight the phage therapy in Gram-positive bacteria and the need for phage therapy in the future. Phage therapy to treat Gram-positive bacterial infections is in use for a very long time. However, limited review on the phage efficacy in Gram-positive bacteria exists. The natural efficiency and potency of bacteriophages against bacterial strains have been advantageous amidst the other non-antibiotic agents. The use of phages to treat oral biofilm, skin infection, and recurrent infections caused by Gram-positive bacteria has emerged as a predominant research area in recent years. In addition, the upsurge in research in the area of phage therapy for spore-forming Gram-positive bacteria has added a wealth of information to phage therapy.
We conclude that the need of phage as an alternative treatment is obvious in future. However, phage therapy can be used as reserve treatment. This review focuses on the potential use of phage therapy in treating Gram-positive bacterial infections, as well as their therapeutic aspects. Furthermore, we discussed the difficulties in commercializing phage drugs and their problems as a breakthrough medicine.
病原菌中的抗生素耐药性已引发全球紧急情况，促使人们寻找替代疗法。噬菌体在一个多世纪前就被发现，并且已被证明在抗生素治疗失败时是一种成功的替代方法。本综述讨论了针对革兰氏阳性病原体的噬菌体疗法的科学研究以及噬菌体疗法临床试验和商业化的总体前景。
本综述旨在强调革兰氏阳性菌中的噬菌体疗法以及未来对噬菌体疗法的需求。用于治疗革兰氏阳性菌感染的噬菌体疗法已经使用了很长时间。然而，关于噬菌体对革兰氏阳性菌疗效的综述有限。在其他非抗生素药物中，噬菌体对细菌菌株的天然效率和效力具有优势。近年来，使用噬菌体治疗口腔生物膜、皮肤感染以及由革兰氏阳性菌引起的复发性感染已成为一个主要的研究领域。此外，针对形成芽孢的革兰氏阳性菌的噬菌体疗法研究热潮为噬菌体疗法增添了丰富的信息。
我们得出结论，未来噬菌体作为替代治疗方法的需求显而易见。然而，噬菌体疗法可作为备用治疗方法。本综述重点关注噬菌体疗法在治疗革兰氏阳性菌感染方面的潜在用途及其治疗方面。此外，我们讨论了噬菌体药物商业化的困难以及它们作为突破性药物存在的问题。
